metoprolol has been researched along with Retinal Detachment in 2 studies
Metoprolol: A selective adrenergic beta-1 blocking agent that is commonly used to treat ANGINA PECTORIS; HYPERTENSION; and CARDIAC ARRHYTHMIAS.
metoprolol : A propanolamine that is 1-(propan-2-ylamino)propan-2-ol substituted by a 4-(2-methoxyethyl)phenoxy group at position 1.
Retinal Detachment: Separation of the inner layers of the retina (neural retina) from the pigment epithelium. Retinal detachment occurs more commonly in men than in women, in eyes with degenerative myopia, in aging and in aphakia. It may occur after an uncomplicated cataract extraction, but it is seen more often if vitreous humor has been lost during surgery. (Dorland, 27th ed; Newell, Ophthalmology: Principles and Concepts, 7th ed, p310-12).
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 1 (50.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 1 (50.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
Authors | Studies |
---|---|
Dmuchowska, DA | 1 |
Zalewska, R | 1 |
Jasiewicz, M | 1 |
Krasnicki, P | 1 |
Mikita, A | 1 |
Sobkowicz, B | 1 |
Mariak, Z | 1 |
Sarraf, D | 1 |
Avci, R | 1 |
Deutman, AF | 1 |
Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
---|---|---|---|---|---|---|---|
Short-Term Oral Mifepristone for Central Serous Chorioretinopathy. A Placebo-controlled Dose Ranging Study of Mifepristone in the Treatment of CSC (STOMP-CSC)[NCT02354170] | Phase 2 | 16 participants (Actual) | Interventional | 2015-01-31 | Completed | ||
[information is prepared from clinicaltrials.gov, extracted Sep-2024] |
2 other studies available for metoprolol and Retinal Detachment
Article | Year |
---|---|
Diagnostic and Therapeutic Challenges.
Topics: Amlodipine; Antihypertensive Agents; Diagnosis, Differential; Drug Therapy, Combination; Female; Hum | 2015 |
[Treatment of central serous choroidopathy with the beta receptor blocker metoprolol (preliminary results)].
Topics: Administration, Oral; Adult; Chorioretinitis; Dose-Response Relationship, Drug; Drug Administration | 1993 |